IMRT 2018
Survival for inoperable early stage NSCLC before SBRT
Cancer-specific survival
OS @ 2 yrs: 33-72% OS @ 3 yrs: 17-55% OS @ 5 yrs: 0-42%
Wisnivesky JP et al., Chest 2005
Made with FlippingBook - professional solution for displaying marketing and sales documents online